Sigan Industries Group Inc. Initiates Class II Recall of Walgreens Acne Cleanser Due to Benzene Contamination
Sigan Industries Group Inc. has initiated a Class II recall of 13,440 tubes of Walgreens Acne Control Cleanser (10% Benzoyl Peroxide) due to benzene contamination. This Canadian-based manufacturer's action impacts U.S. nationwide distribution. Procurement and regulatory teams must assess immediate supply chain risks and review quality protocols for outsourced OTC products.
Recall Details: Benzene Contamination in OTC Acne Treatment
Sigan Industries Group Inc., based in Brampton, Canada, has initiated a voluntary Class II recall, designated D-0274-2025, for 13,440 tubes of Walgreens Acne Control Cleanser. This product, formulated with 10% Benzoyl Peroxide as an acne treatment, was distributed nationwide across the U.S. The critical issue identified is chemical contamination, specifically the presence of benzene, a known human carcinogen. The affected product bears Lot#: 23-09328 and has an expiration date of September 2025. This recall, initiated on February 28, 2025, and reported to the FDA on March 19, 2025, is currently ongoing. For procurement directors, this event necessitates an immediate audit of all incoming raw materials and finished products, particularly those sourced from contract manufacturers for topical applications. Regulatory affairs heads must verify that their internal quality systems are robust enough to detect unexpected contaminants like benzene, which can arise from raw material impurities or manufacturing processes. Supply chain VPs should promptly identify and quarantine any affected lots within their distribution networks to prevent further market exposure and mitigate potential consumer health risks, thereby safeguarding brand reputation and avoiding costly remediation efforts.
Supply Chain Vulnerabilities and Private Label Brand Risk
This recall underscores the inherent risks associated with outsourcing manufacturing, particularly for private label brands such as Walgreens. Sigan Industries Group Inc. acted as the contract manufacturer for Walgreens Co., highlighting the critical importance of rigorous vendor qualification and ongoing oversight. The discovery of benzene in a widely distributed over-the-counter (OTC) product signals potential vulnerabilities in the upstream supply chain, either through contaminated raw materials or issues within the manufacturing process itself at the Brampton, Canada facility. Business development executives contemplating private label partnerships must prioritize comprehensive due diligence on potential contract manufacturers' quality management systems and regulatory compliance history. Procurement teams sourcing active pharmaceutical ingredients (APIs) or finished products from third-party facilities, especially those in international jurisdictions like Canada supplying the U.S. market, must implement enhanced auditing protocols. This incident mandates a review of existing contractual agreements to ensure robust liability clauses, stringent quality assurance mandates, and clear specifications for impurity profiles, protecting both the consumer and the brand from unforeseen chemical contamination events.
Navigating Regulatory Scrutiny and Remediation Requirements
The FDA's classification of this as a Class II recall indicates that while the probability of serious adverse health consequences is remote, the use of or exposure to the product may cause temporary or medically reversible adverse health consequences. This classification means Sigan Industries Group Inc. is now under significant regulatory scrutiny to identify the root cause of the benzene contamination. The company will be expected to conduct a thorough investigation, implement corrective and preventive actions (CAPA), and provide detailed reports to the FDA. Regulatory affairs heads should anticipate increased scrutiny on similar topical OTC product categories containing Benzoyl Peroxide or other chemical ingredients that could potentially degrade or react to form benzene. Companies in this space should proactively review their manufacturing processes, raw material specifications, and stability testing protocols to preclude benzene formation or contamination. Supply chain VPs must prepare for potential disruptions if Sigan faces further regulatory action or if other manufacturers are compelled to re-evaluate their processes, which could impact ingredient availability or increase compliance costs across the industry. This event reinforces the need for continuous monitoring of contract manufacturing organizations (CMOs) to ensure ongoing compliance and maintain product safety standards.